• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Multimodal and interdisciplinary interventions for long term pain]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multigene panel testing for tumors of known origin]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain – a health technology assessment]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Multicentre study to analyse the effectiveness of telemedicine in spirometry quality assurance programmes]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Multicentered randomized controlled trial to test the cost effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom surgical treatment is considered]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2006     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report.]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [MSCT coronary angiography in patients with stable and unstable angina: a multicenter study]
2011     Haute Autorite de sante (HAS) [MRI-guided vacuum-assisted breast biopsy (VABB)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [MRI enterography for the assessment of inflammatory bowel disease]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Motorized Intramedullary nails for bone lenghtening in achondroplasia or hypochondropasia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Motor rehabilitation using ARMEO]
2009     Committee for New Health Technology Assessment (CNHTA) [Motor cortex stimulation]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Motivational interviewing for HIV-related behaviors among men who have sex with men]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Motivational interviewing embedded in planned diabetes care for Type 2 patients: effectiveness and efficiency in general practice especially to improve guideline recommendations on diet and exercise]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mosunetuzumab (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [More efficient use of corneal donor donations: the Dutch Lamellar Corneal Transplantation Study (DLCTS-Study)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Montelukast in patients with chronic allergic rhinitis and no asthma]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2013     Andalusian Health Technology Assessment Area (AETSA) [Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency]
2020     Canary Health Service [Monitoring study: “Endobronchial valves for persistent air leak”]
2021     Canary Health Service [Monitoring study: "The sensor glucose monitoring system (flash-type) for type 1 diabetes mellitus in childhood and adolescence"]
2015     Canary Health Service [Monitoring study protocol (part I): endobronchial valves for persistent air leakage]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of stable glaucoma patients: evaluation of the effectiveness and efficiency of a glaucoma follow-up unit, staffed by nonphysician health care professionals, as an intermediate step towards glaucoma monitoring in primary care]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study)]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Monitoring depth of anaesthesia - a health technology assessment]
2015     Canary Health Service [Monetary value of a quality-adjusted life year: empirical estimation of the opportunity cost in the national health system]
2014     Canary Health Service [Monetary value of a quality-adjusted life year: a critical review and appraisal of the literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2021     Canary Health Service [Molecular markers for the detection of clinically significant prostate cancer]
2011     The Swedish Council on Health Technology Assessment (SBU) [Molecular diagnostic tests for men at higher probability for prostate cancer]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mogamulizumab (mycosis fungoides or Sézary syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Haute Autorite de sante (HAS) [Modification of the nomenclature of procedures in laboratory medicine for research into Treponema pallidum (bacteria responsible for syphilis)]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Models of lower back pain: reliability of a classification model]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Models of collaboration and intervention between primary care and mental health in the care of patients diagnosed with depression: results of a meta-review]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Models for providing care and services to patients who have concurrent mental health and substance use disorders]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mobility disorders: does the Feldenkrais method help?]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Mistletoe therapy with breast cancer]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Misoprostol for induction of labour]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirabegron - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2003     Basque Office for Health Technology Assessment (OSTEBA) [Minimum characteristics of a cardiac rehabilitation programme in the Basque Autonomous Community]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Migraine surgery]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Miglustat for patients with niemann-pick disease type C]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) in the treatment of Niemann-Pick type C disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) for patients with type 1 Gaucher's disease]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Migalastat for Fabry disease]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Addendum to Commission A23-88]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2011     Committee for New Health Technology Assessment (CNHTA) [Microvolt T-wave alternans system]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2012     Andalusian Health Technology Assessment Area (AETSA) [MicroRNAs as a diagnostic tool for lung cancer]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Microperimetry in retinopathies]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Micrometastases and isolated tumour cells: relevant and robust or rubbish? The MIRROR study in breast cancer]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Microinvasive glaucoma surgery (MIGS) - Hydrus Microstent for the treatment of mild to moderate glaucoma]
2009     Committee for New Health Technology Assessment (CNHTA) [Microdeletion syndrome screening test(MLPA)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Microdebrider in nose-throat surgeries]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microbial collagenase from Clostridium histolyticum - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mexiletine (myotonia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metreleptin (lipodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Methylnaltrexone for opioid-induced constipation in cancer treatment]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Methods to increase chronically ill patients' participation in health care and services]
2012     The Swedish Council on Health Technology Assessment (SBU) [Methods to estimate and measure renal function (glomerular filtration rate)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Methods of diagnosis and treatment in endodontics - a systematic review of the literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Methods for assessment of innovative medical technologies during early stages of development]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: support for the implementation of a pilot project on the targeted use of medications for the treatment of obesity in designated centers]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2007     Canary Health Service [Methodology for incorporating qualitative studies in health technology assessment]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Methodological project: Synthesis of information in support of multicriteria decision analysis (MCDA) for decision making]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metformin: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Meropenem/vaborbactam (bacterial infections, several therapeutic indications) - Assessment in accordance with § 35a (1c) Social Code Book (SGB) V ]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Addendum to Commission A21-152]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Addendum to Commission A21-151]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab - Benefit assessment according to §35a Social Code Book V]